ÖØÉúºó·ÏÎïÌìÌì¶¼ÔÚ´òÁ³_Âþ»æÍ¼Æ¬_ɨÎļͼ_¶¯Âþ_ÂþÆÀ..."/> Èü³µÔ˶¯ÐèÒªµÄ²»µ«ÊÇËÙÂÊÓë¼¼ÇÉ£¬¸üÊÇÍŶӵÄÐ×÷ÓëĬÆõ¡£ÍõÒ»²©Óë¶ÓÓÑÅ˾ýÁÙµÄÅäºÏ£¬ÕýÊÇËûÃǶá¹ÚµÄÖ÷ÒªÒòËØ¡£ÔÚ½ÇÖðÖУ¬Á½ÈËÏ໥ÐÅÈΣ¬³ä·ÖÑéÕ¹¸÷×ÔµÄÓÅÊÆ£¬×îÖÕÅäºÏÅõÆðÁ˹ھü½±±¡£ÕâһʤÀû²»µ«ÊǶÔËûÃÇÆð¾¢µÄ»Ø±¨£¬Ò²ÎªÎ´À´µÄ½ÇÖðµÓÚ¨ÁËÐÅÐÄ¡£"/>
¡¶ÖØÉúºó·ÏÎïÌìÌì¶¼ÔÚ´òÁ³_Âþ»æÍ¼Æ¬_ɨÎļͼ_¶¯Âþ_ÂþÆÀ...¡·¾çÇé¼ò½é£ºÈü³µÔ˶¯ÐèÒªµÄ²»µ«ÊÇËÙÂÊÓë¼¼ÇɸüÊÇÍŶӵÄÐ×÷ÓëĬÆõÍõÒ»²©Óë¶ÓÓÑÅ˾ýÁÙµÄÅäºÏÕýÊÇËûÃǶá¹ÚµÄÖ÷ÒªÒòËØÔÚ½ÇÖðÖÐÁ½ÈËÏ໥ÐÅÈγä·ÖÑéÕ¹¸÷×ÔµÄÓÅÊÆ×îÖÕÅäºÏÅõÆðÁ˹ھü½±±ÕâһʤÀû²»µ«ÊǶÔËûÃÇÆð¾¢µÄ»Ø±¨Ò²ÎªÎ´À´µÄ½ÇÖðµÓÚ¨ÁËÐÅÐÄÀîγîÒ»½£»÷·ÉÍ·¶¥ÕÉÐíÀ´³¤µÄ¹öľÁ³ÉϺÝɫһÉÁ×ßÁ¬Ã¦Í˳öÕâÀïÖØÉúºó·ÏÎïÌìÌì¶¼ÔÚ´òÁ³_Âþ»æÍ¼Æ¬_ɨÎļͼ_¶¯Âþ_ÂþÆÀ...¾ÍÔÚÕâ¸öʱ¼äÍõÒ»µ¶×ßµ½ÁËëÁϵÄÑÛǰ×îÏÈÉó²éëÁÏÕâ¿ÉÊÇËûºÃ½ûÖ¹Ò×ÌôÑ¡µÄëÁϲ¢ÇÒÕվɵ±×ÅËùÓÐÈ˵ÄÃæ½â¿ªµÄÒÔÊDz»¿É¶È¿à°¡Ã÷ÐǵÄСÎÒ˽¼ÒÓ°ÏìÁ¦³ÉΪËûÃǸҶ¨¸ß¼Û¡¢´óµ¨Òç¼ÛµÄµ×Æø¿ÉÊdz±Æð³±Â䳱ůÉúÒâÔçÒѹýÁËËÈËÌù¸öLOGO¾ÍÄÜÍÑÏúµÄ²ÝҰʱ´ú
¡¶ÖØÉúºó·ÏÎïÌìÌì¶¼ÔÚ´òÁ³_Âþ»æÍ¼Æ¬_ɨÎļͼ_¶¯Âþ_ÂþÆÀ...¡·ÊÓÆµËµÃ÷£ºYang C.W. et al. CD34+ cell transfusion in CKD: phase II clinical trial. Nephrology Dialysis Transplantation, 2020.4??²¤²Ë¼¦µ°¾í
²»¹ýËýµÄ»°µ¹ÊÇûÓмÙδ¼¸Ê±Ä½Èݸ´±ã¼ûǰ·½´«À´Ò»Ä¨ÁÁ¹âÐеÃÊýÕÉÊÓÒ°ÝëȻ̹µ´ÆðÀ´È´ÊÇÒ»¸öÖØ´óµÄ×ÔÈ»¶´Ñ¨Ò«ÑÛµÄÑô¹â´Ó¶´Ñ¨¶¥ÉÏÉä½øÀ´³ø·¿ÊǼÒÍ¥»ðÔÖµÄÖØÔÖÇøÆäÖÐÒ»¸öÖ÷ÒªÔµ¹ÊÔÓÉÊÇÓûðÀëÈË¿ËÈÕ±±¾©ÊÐÃÜÔÆÇøÏû·À¾ÈÔ®Ö§¶Ó½Óµ½ÈýÆð³ø·¿Æð»ðÔÖÇéÔµ¹ÊÔÓɾùÊÇסÃñ¿ª»ð×ö·¹Ê±ÓÉÓÚÆäËûÊÂÇéÍÑÀë³ø·¿µ¼ÖÂÓ͹øÆð»ðËùÐÒÈýÆð»ðÔÖÒòʵʱÆË¾È¾ùδÔì³ÉÖ°Ô±ÉËÍö
½ôÁ˽ôÊÖÖÐ˶´óµÄǰÎÀ3µ¥±ø·À¿Õµ¼µ¯Ñî¿É¶ù²»ÓɵÄÏëÆð֮ǰÔÚÕ¹ÍûµÄʱ¼äËÆºõ×ÜÓÐһƬ¿ÕȱËýûÓÐË¿ºÁÓ¡ÏóËÆºõÊܵ½ÁËʲô×ÌÈÅÕâÖÖÇéÐδÓû·ºÆð¹ýÒÔǰ×ÝÈ»ÔÚÄ£ºýËýÒ²ÄÜ»ØÒäÆð´óÖµÄÂöÂç¿ÉÊÇÕâ´Î¡¡ÐãÖ¥ÕâôÍíÁËÄãÔõôÀ´ÁË
2025-09-22 14:56:51